Core Viewpoint - Yipinhong announced that its wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of Fuganlin granules for treating adult Qi deficiency cold [2] Group 1 - The clinical trial approval notification number is 2025LP02464 [2] - The application acceptance number for the drug is CXZL2500048 [2] - The clinical trial is specifically aimed at adults suffering from Qi deficiency cold [2]

Core Viewpoint - Yipinhong Pharmaceutical (300723.SZ) has received approval from the National Medical Products Administration for clinical trials of its Fuganlin granules, aimed at treating adult patients with Qi deficiency cold [1] Group 1 - Yipinhong Pharmaceutical's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., is responsible for the development of Fuganlin granules [1] - The clinical trial approval indicates a significant step forward in the company's product pipeline and potential market expansion [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its drug, Fuganlin Granules, aimed at treating adult patients with Qi deficiency cold [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., is responsible for the drug's clinical trial application [1] - The approval allows the company to proceed with clinical trials for Fuganlin Granules, indicating progress in its product development pipeline [1] Group 2: Industry Context - The approval of new drugs is a critical step in the pharmaceutical industry, reflecting regulatory support for innovative treatments [1] - Conducting clinical trials is essential for validating the efficacy and safety of new medications, which can impact market competitiveness [1]

Group 1 - The core point of the article is that Yipinhong Pharmaceutical's subsidiary has received approval for clinical trials of a new drug aimed at treating adult patients with Qi deficiency cold [1] Group 2 - Yipinhong Pharmaceutical's subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has been granted a clinical trial approval notice by the National Medical Products Administration [1] - The drug being tested is called Fuganling Granules, which is intended for use in adults suffering from Qi deficiency cold [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its drug, Fuganlin Granules, aimed at treating adult patients with Qi deficiency cold [1] Group 1 - The full subsidiary of the company, Guangzhou Yipin Hong Pharmaceutical Co., Ltd., is responsible for the drug's development [1] - The clinical trial approval notification number is 2025LP02464, indicating formal recognition by regulatory authorities [1] - The acceptance number for the drug application is CXZL2500048, which is part of the regulatory process [1]